Galapagos Stock: 5.87% Decline at Close Following Announcement of Halting Cell Therapy Operations
The stock of Belgian biotech company Galapagos ended the session on Tuesday, October 21, with a sharp decline of 5.87%, closing at 27.88 euros. This drop occurred in an otherwise favorable stock market environment, with the CAC 40 showing a gain of 0.64% over the same period. Trading volumes were high, with 1.72% of the capital changing hands during the day.
After closing at 29.62 euros on Monday, Galapagos stock opened significantly lower on Tuesday, finishing below the 28 euros mark. This correction is part of a challenging weekly dynamic, with the stock experiencing a decline of 5.68% over seven days. Volatility remains pronounced with a one-month indicator at 9.42, indicating significant movement amplitudes. However, a beta of 0.32 suggests a moderate sensitivity to market fluctuations. Over a longer horizon, the situation appears more mixed. While the stock shows a positive quarterly performance of 3.72%, the annual balance remains almost stable with a slight decline of 0.07%. This relative resilience contrasts with the significant rise of the CAC 40, which has increased by 8.48% over the year, highlighting the specific challenges faced by the company.
Strategic Transformation and Market Impact
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
This downward movement comes after Galapagos announced its decision to discontinue its cell therapy operations as part of a strategic transformation of the company. This decision led to a sharp drop in the stock during pre-market trading, amplifying selling pressure throughout the day. The Belgian biotech, which had already left the BEL 20 index in favor of Montea last March, continues its restructuring in a highly competitive and demanding biotechnological sector.
Technical Analysis of Stock Movements
From a technical standpoint, the closing price of 27.88 euros is now slightly below the 50-day moving average set at 28.35 euros, but remains above the 200-day moving average at 28.16 euros. The RSI is at 53, in a neutral zone that indicates neither overbought nor oversold conditions. The MACD indicator shows a negative histogram at -0.13, with a MACD line at 0.36 and a signal line at 0.49, suggesting a weakness in momentum. The Bollinger Bands frame the stock between 27.59 euros in support and 31.38 euros in resistance. The immediate technical support threshold is at 26.84 euros, while the first notable resistance appears at 31.84 euros. The Chaikin Money Flow at -0.04 indicates a slight selling pressure on volumes.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 18,6 millions d'euros
Quarterly revenue: 18,6 millions d'euros
Revenue growth: -86,7 %
Net income: 16,6 millions d'euros
Guidance from the release
Maintain year-end 2026 cash guidance of ~€2B, forecast at least €1.6B remaining after portfolio funding
Risks mentioned
Wind-down of cell therapy activities remains ongoing with completion expected by Q3 2026, representing significant portfolio contraction and operational disruption
Collaboration revenues declined 96% year-over-year to €4.5M (from €121.8M in H1 2025) due to full deferred revenue recognition from Gilead platform agreement in 2025
Heavy dependence on gamgertamig development success and regulatory approval timeline; clinical development delays or unfavorable data could materially impact capital allocation and company viability
Opportunities identified
Acquisition of Ouro Medicines completed in June 2026, combining Lakefront and Gilead teams to accelerate gamgertamig development with expected additional proof-of-concept basket studies in autoimmune indications during 2027
Gamgertamig has received Fast Track and Orphan Drug Designation from FDA for AIHA and ITP, with registrational studies expected to commence in 2027
Lakefront maintains strong capital position with €2.24B in cash and investments as of June 30, 2026, providing substantial dry powder (€1.6B minimum) for strategic transactions after portfolio funding to first approval
Outlook / guidance
Expected revenue: 2 013 millions d'euros
Management commentary: Maintain year-end 2026 cash and financial investments balance guidance of ~€2B, and now includes €50M share repurchase. Lakefront forecasts having at least €1.6 billion of its cash remaining for additional strategic transactions and other capital allocation priorities.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
